A5009613880- Schizophrenia research and treatment
- Neonatal Respiratory Health Research
- Genetic Neurodegenerative Diseases
- Bipolar Disorder and Treatment
- Gastrointestinal motility and disorders
- Neurological disorders and treatments
- Health Systems, Economic Evaluations, Quality of Life
- Attention Deficit Hyperactivity Disorder
- Diabetes Treatment and Management
- Pharmaceutical studies and practices
- Hemophilia Treatment and Research
- Statistical Methods in Clinical Trials
- Congenital Diaphragmatic Hernia Studies
- Migraine and Headache Studies
- Treatment of Major Depression
- Advanced Breast Cancer Therapies
- Prostate Cancer Treatment and Research
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Causal Inference Techniques
- Cystic Fibrosis Research Advances
- Infant Development and Preterm Care
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Medication Adherence and Compliance
Analysis Group (United States)
2015-2024
Teva Pharmaceuticals (United States)
2019
Ibero American University
2018
Boston University
2014
Vrije Universiteit Amsterdam
2013
Information Management Services
2005-2008
National Cancer Institute
2006-2008
Division of Cancer Epidemiology and Genetics
2008
Georgetown University
2006
National Institutes of Health
2006
To improve the discriminatory power of Gail model for predicting absolute risk invasive breast cancer, we previously developed a relative that incorporated mammographic density (DENSITY) from data on white women in Breast Cancer Detection Demonstration Project (BCDDP). That also included variables age at birth first live child (AGEFLB), number affected mother or sisters (NUMREL), previous benign biopsy examinations (NBIOPS), and weight (WEIGHT). In this study, corresponding risk.We combined...
Vesicular monoamine transporter 2 (VMAT2) inhibitors can improve hyperkinetic movements, and are effective treatment options for chorea of Huntington disease (HD). Tetrabenazine was assessed treating in the TETRA-HD trial, while efficacious, there tolerability concerns possibly due to its pharmacokinetic properties. Deutetrabenazine is a novel VMAT2 inhibitor that contains deuterium, which extends active metabolite half-lives minimizes drug concentration fluctuations. In First-HD...
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety fremanezumab prevention have been demonstrated randomized, double-blind, placebo-controlled trials. Real-world effectiveness data are needed to complement clinical trial data. This study assessed across different subgroups adult patients with episodic (EM),...
Background: Infants born extremely preterm are at high risk of developing bronchopulmonary dysplasia (BPD). This study aimed to assess the incremental health care burden BPD and associated comorbidities among infants in United States. Methods: Health service claims Premier Perspective database were retrospectively analyzed for ≤28 weeks gestation who admitted neonatal intensive during birth hospitalization survived a postmenstrual age ≥36 weeks. Results: Of 12,017 included, 4904 (40.8%) had...
No published head-to-head randomized trials have compared the safety and efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration-resistant prostate cancer. This study compares prespecified adverse events metastasis-free survival associated with apalutamide, enzalutamide, via matching-adjusted indirect comparisons.Individual patient data from phase III ARAMIS trial (NPLACEBO=553; NDAROLUTAMIDE=943) were selected reweighted to match inclusion criteria baseline...
Abstract Background Due to limited treatment options, many patients with diabetic gastroparesis (DG) or idiopathic (IG) experience inadequate symptom control resulting in increased health‐care resource utilization (HRU) and associated costs. We compared all‐cause HRU costs over the 3 years after patients’ first diagnosis that of matched controls without gastroparesis. Methods Newly diagnosed adults DG IG were identified Optum's de‐identified Clinformatics ® Data Mart Database (Q1‐2007...
The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) is approved for the preventive treatment migraine in adults, have been demonstrated randomized, double-blind, placebo-controlled trials. Real-world data can further support those clinical trial demonstrate full benefits fremanezumab. This chart review assessed effectiveness fremanezumab improving outcomes adult patients with treated...
Tardive dyskinesia (TD) is a serious, often irreversible movement disorder caused by prolonged exposure to antipsychotics; identifying patients at risk for TD critical preventing it. Predictive models the occurrence of can improve patient monitoring and inform implementation counteractive interventions. This study aims identify factors associated with develop model using retrospective data analysis predict incidence among taking antipsychotic medications.Adult schizophrenia, major depressive...
Data are limited on the benefits and risks of dose reduction in managing side effects associated with antipsychotic treatment. As an example, has been recommended management tardive dyskinesia (TD), yet lowering doses not well studied. However, stable maintenance treatment is essential to prevent deterioration relapse schizophrenia.A retrospective cohort study was conducted analyze healthcare burden patients schizophrenia. Medical claims from six US states spanning a six-year period were...
Indirect comparisons of treatment-specific outcomes across separate studies often inform decision making in the absence head-to-head randomized comparisons. Differences baseline characteristics between study populations may introduce confounding bias such Matching-adjusted indirect comparison (MAIC) (Pharmacoeconomics 28 (2010) 935–945) has been used to adjust for differences observed covariates when individual patient-level data (IPD) are available only one and aggregate (AGD) other study....
Information regarding the comparative efficacy of first-generation receptor tyrosine kinase inhibitors is limited. This matching-adjusted indirect comparison (MAIC) evaluated differences in and safety across larotrectinib entrectinib trials. Data from clinical trials for (LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), NAVIGATE (NCT02576431)) (ALKA-372-001 (EudraCT 2012-000148-88), STARTRK-1 (NCT02097810), STARTRK-2 (NCT02568267)) were used. Adults (≥18 years) matched on available...
Irritable bowel syndrome (IBS) reduces quality of life and burdens healthcare systems. This study identified factors associated with frequent use IBS diagnostic tests procedures.Using a United States claims database (2001-2012), procedures in patients occurring the 2-year period (12 months before/following first diagnosis) were analyzed: endoscopy, GI transit testing, anorectal procedures, radiologic imaging. Patients classified based on test/procedure frequency (3+, 1-2, or 0). Multivariate...
Objective: To evaluate the prevalence of chronic respiratory morbidity (CRM) in preterm infants (born ≤28 weeks gestational age (GA)) and compare healthcare resource utilization costs among with/without CRM, bronchopulmonary dysplasia (BPD).Methods: Commercial claims data from Truven MarketScan database were retrospectively analyzed. Included born GA admitted to a neonatal intensive care unit (January 2009–June 2016). Continuous insurance eligibility was required birth through 1 year (CRM/no...
Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine severe AD ??1 year. The efficacy/effectiveness of these treat?ments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Severity Index (EASI) EASI-50/EASI-75 at weeks 12?16 24?30) dupilumab 300 mg every 2 (CHRONOS [NCT02260986]) or (University Medical Center). Models were adjusted sex, baseline EASI, thymus activation-regulated chemokine...
Aims: To evaluate the association of relapse and healthcare resource utilization in patients with schizophrenia (SZ), bipolar disorder (BD), or major depressive (MDD) who switched antipsychotic medication versus those did not.Materials methods: Medicaid claims from six US states spanning years were retrospectively analyzed for switching non-switching. For all SZ, BD, MDD, subset also had ≥1 extrapyramidal symptoms (EPS) diagnosis at baseline, times to following outcomes analyzed: underlying...
AbstractObjective:This study aims to develop and validate a stroke risk model incorporating pulse pressure (PP) as potential factor. Recent evidence suggests that PP, defined the difference between systolic blood (SBP) diastolic (DBP), could be an incremental factor beyond SBP.Methods:Electronic health records (EHRs) of hypertensive patients from US integrated delivery system were analyzed (January 2004 May 2012). Patients with ≥1 PP reading ≥6 months observation prior first diagnosis...
When and how to intensify treatment in patients with type 2 diabetes (T2D) not achieving glycated hemoglobin (HbA1c) targets oral antidiabetic drugs (OADs) clinical practice remains a matter of preference. This pilot study was conducted using the retrospective observational data from such evaluate impact on HbA1c three sequences: simultaneous initiation basal insulin (BI) glucagon-like peptide-1 receptor agonist (GLP-1 RA; Cohort 1); BI followed by GLP-1 RA within 90-day timeframe (Cohort...